Skip to content
Mainboard BSE,NSE Bidding closed

Sudeep Pharma IPO Subscription Status

Sudeep Pharma IPO received bids for 99,01,00,150 shares against 1,05,64,926 offered, an overall subscription of 93.72x at the close of bidding (25 Nov 2025). QIBs lead at 213.08x.

Last updated · day 3 figures

Retail
15.65x
NII
116.72x
QIB
213.08x
Total
93.72x

Where the demand is

Sudeep Pharma IPO subscription by category Each line starts at 1x (fully subscribed) and ends at the category's subscription multiple, on a logarithmic scale. Values are listed in the table below. 0.1x 1x 10x 100x 1,000x QIB QIB: 213.08x 213.08x NII NII: 116.72x 116.72x bNII bNII: 134.91x 134.91x sNII sNII: 80.33x 80.33x Retail Retail: 15.65x 15.65x Total Total: 93.72x 93.72x
Log scale. Lines run from 1x (fully subscribed): right means more demand than shares, left means shares still unbid.

Sudeep Pharma IPO subscription by category

Category Shares offered Shares bid Amount bid Subscription
QIB 30,18,550 64,31,88,450 ₹38,141.08 Cr 213.08x
NII 22,63,913 26,42,40,450 ₹15,669.46 Cr 116.72x
bNII above ₹10 lakh 15,09,276 20,36,19,700 ₹12,074.65 Cr 134.91x
sNII ₹2–10 lakh 7,54,637 6,06,20,750 ₹3,594.81 Cr 80.33x
Retail 52,82,463 8,26,71,250 ₹4,902.41 Cr 15.65x
Total 1,05,64,926 99,01,00,150 ₹58,712.94 Cr 93.72x

* Shares Offered and Total Amount are calculated based on the upper price of the issue price range. * The portion of anchor investors (or market makers) is not included in the total number of shares offered.

Sudeep Pharma IPO subscription day-wise

Category Day 3
QIB 213.08x
NII 116.72x
bNII 134.91x
sNII 80.33x
Retail 15.65x
Total 93.72x
Total added 93.72x

Cumulative figures at the end of each day. Read across a row to see how demand built up. Shading deepens as subscription rises above 1x; "Total added" is how much overall subscription grew that day.

Sudeep Pharma IPO reservation

Category Shares Share of issue
Qualified Institutional Buyers 30,18,550 28.57%
Non-Institutional Investors 22,63,913 21.43%
bNII · above ₹10 lakh 15,09,276 67% of NII
sNII · ₹2–10 lakh 7,54,637 33% of NII
Retail Individual Investors 52,82,463 50.00%
Public issue 1,05,64,926 100%

Allotment Chances Note

These are estimates from the latest application and subscription figures. Actual chances are usually somewhat better, because:

  • Not every bid is at the cut-off price. Bids below the final issue price are rejected before the lottery, so fewer applications compete.
  • Multiple-lot applications count once. In an oversubscribed retail or sNII portion, each application gets at most one minimum lot in the draw, however many lots it bid for.
  • Invalid applications drop out. Unapproved UPI mandates, PAN mismatches and duplicate applications are removed before allotment.

Applying for more lots in the retail category does not improve your odds; applying from separate family accounts does.

Sudeep Pharma IPO subscription: FAQs

What is the overall subscription of Sudeep Pharma IPO?
Sudeep Pharma IPO is subscribed 93.72x overall as of day 3 (25 November 2025), with bids for 99,01,00,150 shares against 1,05,64,926 offered.
What is the retail subscription of Sudeep Pharma IPO?
The retail portion is subscribed 15.65x as of day 3 (25 November 2025).
What is the QIB and NII subscription of Sudeep Pharma IPO?
QIBs have subscribed 213.08x of their portion, and NIIs 116.72x (bNII 134.91x, sNII 80.33x) as of day 3 (25 November 2025).
How can I check Sudeep Pharma IPO subscription status live?
This page shows category-wise and day-wise figures and is updated during bidding hours. The same data is published on the BSE and NSE websites under the issue name.
How do I apply for Sudeep Pharma IPO?
Apply online through your broker or bank using UPI or ASBA. Choose the IPO, enter the number of lots and bid price (retail investors can bid at the cut-off price), and approve the UPI mandate before the issue closes on 25 November 2025.

Subscription figures are compiled from BSE and NSE bid data and can be revised by the exchanges after the issue closes. For information only; not investment advice.